1. Volume 69, Issue 5, Pages 924-932 (May 2016)
Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies 
Joaquim Bellmunt, Thian Kheoh, Margaret K. Yu, Matthew R. Smith, Eric J. Small, Peter F.A. Mulders, Karim Fizazi, Dana E. Rathkopf, Fred Saad, Howard I. Scher, Mary-Ellen Taplin, Ian D. Davis, Dirk Schrijvers, Andrew Protheroe, Arturo Molina, Peter De Porre, Thomas W. Griffin, Johann S. de Bono, Charles J. Ryan, Stéphane Oudard 
European Urology 
Volume 69, Issue 5, Pages (May 2016)
DOI: /j.eururo
Copyright © 2015 European Association of Urology Terms and Conditions

2. Fig. 1
Consolidated Standards of Reporting Trials diagram for (A) COU-AA-301 and (B) COU-AA-302.
AA=abiraterone acetate; GnRH=gonadotropin-releasing hormone; ITT=intention-to-treat; P=prednisone.
European Urology  , DOI: ( /j.eururo )
Copyright © 2015 European Association of Urology Terms and Conditions

3. Fig. 2
Radiographic progression-free survival Kaplan-Meier estimates in COU-AA-301 patients with prior endocrine therapy exposure by duration in quartiles for (A) gonadotropin-releasing hormone agonists and (B) androgen receptor antagonists.
AA=abiraterone acetate; CI=confidence interval; HR=hazard ratio; P=prednisone; rPFS=radiographic progression-free survival; Q=quartile.
European Urology  , DOI: ( /j.eururo )
Copyright © 2015 European Association of Urology Terms and Conditions

4. Fig. 3
Radiographic progression-free survival Kaplan-Meier estimates in COU-AA-302 patients with prior endocrine therapy exposure by duration in quartiles for (A) gonadotropin-releasing hormone agonists and (B) androgen receptor antagonists.
AA=abiraterone acetate; CI=confidence interval; HR=hazard ratio; P=prednisone; rPFS=radiographic progression-free survival; Q=quartile.
European Urology  , DOI: ( /j.eururo )
Copyright © 2015 European Association of Urology Terms and Conditions